ArticleNature communications2019
Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 98 citations in OpenAlex.
- Trial
- Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Epidermal Growth Factor Receptor-Targeted Fluorescence Molecular Imaging for Postoperative Lymph Node Assessment in Patients with Oral Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Trial
- Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW.Theranostics · 2021Trial
- Automated cGMP optical labeling of FDA-approved antibodies for human use.Nature protocols · 2026Review
- Fluorescence Discrimination of Cancer from Inflammation by Selective Targeting Folate Receptor α.Chemical & biomedical imaging · 2026Article
- c-Met-targeted NIR-II imaging for precision management of oral squamous cell carcinoma and premalignant lesions.Theranostics · 2026Article
- Porphyrin-lipid nanotheranostics for multimodal imaging of nodal disease in preclinical oral cancers.Theranostics · 2026Article
- Use of Dual-Modality Antibody Imaging for Assessment of Lymph Node Metastases in Head and Neck Cancer.Theranostics · 2026Article
- Clinical translation of photoacoustic imaging using exogenous molecular contrast agents [Invited].Biomedical optics express · 2025Review
- Background Tissue with Native Target Expression Can Determine Presence of Nodal Metastasis in Head and Neck Squamous Cell Carcinoma Patients Infused with Targeted Fluorescent Tracers.Molecular imaging and biology · 2025Article
- Towards Optical Biopsy in Glioma Surgery.International journal of molecular sciences · 2025Review
- Molecular-Targeted Fluorescence Lymph Node Imaging Could Play a Clinical Role in the Surgical Setting: A Systematic Review.Cancers · 2025Review
- Fluorescence Lifetime Imaging Enables In Vivo Quantification of PD-L1 Expression and Intertumoral Heterogeneity.Cancer research · 2025Article
- Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.Journal of nanobiotechnology · 2024Review
- Orbital Adipose Tissue: The Optimal Control for Back-Table Fluorescence Imaging of Orbital Tumors.Bioengineering (Basel, Switzerland) · 2024Article
- Illuminating the future of precision cancer surgery with fluorescence imaging and artificial intelligence convergence.NPJ precision oncology · 2024Review
- Infrared Fluorescence-guided Surgery for Tumor and Metastatic Lymph Node Detection in Head and Neck Cancer.Radiology. Imaging cancer · 2024Review
- Progress of fluorescence imaging in lymph node dissection surgery for prostate and bladder cancer.Frontiers in oncology · 2024Review
- Comparative aspects of targeted sentinel lymph node mapping in veterinary and human medicine: opportunities for future research.Frontiers in medicine · 2024Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
Identification of lymph node (LN) metastasis is essential for staging of solid tumors, and as a result, surgeons focus on harvesting significant numbers of LNs during ablative procedures for pathological evaluation. Isolating those LNs most likely to harbor metastatic disease can allow for a more rigorous evaluation of fewer LNs. Here we evaluate the impact of a systemically injected, near-infrared fluorescently-labeled, tumor-targeting contrast agent, panitumumab-IRDye800CW, to facilitate the identification of metastatic LNs in the ex vivo setting for head and neck cancer patients. Molecular imaging demonstrates a significantly higher mean fluorescence signal in metastatic LNs compared to benign LNs in head and neck cancer patients undergoing an elective neck dissection. Molecular imaging to preselect at-risk LNs may thus allow a more rigorous examination of LNs and subsequently lead to improved prognostication than regular neck dissection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.